Molnunat 200 mg contains molnupiravir, an oral antiviral medication developed for the treatment of mild to moderate COVID-19 in adults who are at risk of developing severe illness. It became one of the first oral antivirals authorized for emergency use during the COVID-19 pandemic. Molnupiravir is used early in the course of infection to help reduce hospitalisation and death in vulnerable individuals.

Mechanism of Action
Molnupiravir works by targeting the replication process of the SARS-CoV-2 virus, which causes COVID-19. It is a prodrug that gets converted in the body into its active form. This active form is taken up by the virus’s RNA polymerase and incorporated into its genetic material. Once inside the viral RNA, it causes a buildup of mutations, a process known as “error catastrophe.” These mutations prevent the virus from reproducing properly, ultimately stopping the infection from spreading.

Uses
Molnunat 200 mg is used for:

• Treatment of mild to moderate COVID-19 in adults with risk factors such as older age, diabetes, chronic lung or heart disease, obesity, or a weakened immune system

• It is most effective when given within five days of symptom onset

• It is usually prescribed as a five-day course of oral capsules

  Adverse Effects

  Common side effects include:

  • Headache

  • Dizziness

  • Nausea

  • Diarrhoea